Biomarin Pharmaceutical (BMRN) Free Cash Flow Growth (3y) (2012 - 2026)
Biomarin Pharmaceutical (BMRN) Free Cash Flow Growth (3y) (2012 - 2026) Analysis & Trends
Peer Comparison
| # |
Company |
Market Cap |
Enterprise Value |
Gross Profit (Qtr) |
FCF Growth (3y) (Qtr) |
| 1 |
Alterity Therapeutics |
925,601.88 Bn |
925,601.85 Bn |
- |
- |
| 2 |
Belite Bio |
58,560.00 Bn |
58,560.00 Bn |
- |
- |
| 3 |
Quantum Biopharma |
17,284.41 Bn |
17,284.40 Bn |
- |
- |
| 4 |
Legend Biotech |
2,809.00 Bn |
2,808.71 Bn |
242.10 Mn |
24.91% |
| 5 |
Evaxion A |
1,334.43 Bn |
1,334.42 Bn |
- |
- |
| 6 |
Akari Therapeutics |
1,312.27 Bn |
1,312.26 Bn |
- |
20.11% |
| 7 |
Psyence Biomedical |
212.16 Bn |
212.16 Bn |
- |
- |
| 8 |
Vertex Pharmaceuticals |
114.83 Bn |
107.58 Bn |
2.59 Bn |
14.71% |
| 9 |
Abivax |
91.96 Bn |
91.96 Bn |
- |
- |
| 10 |
Biomarin Pharmaceutical |
10.52 Bn |
8.29 Bn |
571.21 Mn |
59.14% |
| Date | Value |
|---|
| Mar 31, 2026 |
59.14% |
| Dec 31, 2025 |
59.25% |
| Sep 30, 2025 |
38.16% |
| Jun 30, 2025 |
79.51% |
| Mar 31, 2025 |
60.35% |
| Dec 31, 2024 |
125.46% |
| Sep 30, 2024 |
37.37% |
| Jun 30, 2024 |
17.42% |
| Mar 31, 2024 |
-38.11% |
| Dec 31, 2023 |
68.16% |
| Sep 30, 2023 |
17.83% |
| Jun 30, 2023 |
213.39% |
| Mar 31, 2023 |
-20.85% |
| Dec 31, 2022 |
-85.73% |
| Sep 30, 2022 |
51.27% |
| Jun 30, 2022 |
35.91% |
| Mar 31, 2022 |
3.89% |
| Dec 31, 2021 |
-63.95% |
| Sep 30, 2021 |
215.67% |
| Jun 30, 2021 |
45.30% |
